Sales & Marketing

We currently market and sell BioThrax® (Anthrax Vaccine Adsorbed) directly to the DoD and HHS with a small, targeted marketing and sales force. We plan to continue to do so and expect that we will use a similar approach for sales to the U.S. government of any other biodefense product candidates that we successfully develop. We plan to expand our sales and marketing organization as we broaden our sales activities of biodefense products to state and local governments, which we expect will be interested in these products to protect first responders, such as police, fire and emergency medical personnel. We have established marketing and sales offices in Singapore and Munich, Germany to target sales of biodefense products to foreign governments. We also have engaged third party marketing representatives to market BioThrax® (Anthrax Vaccine Adsorbed) in the Middle East, Turkey, India, Australia and several Scandinavian countries in Europe.

We expect to establish a separate internal organization to market and sell commercial products for which we retain commercialization or co-commercialization rights. We anticipate that our internal marketing and sales organization will be complemented by selective co-promotion and other arrangements with leading pharmaceutical and biotechnology companies.

We generally expect to retain commercial rights for our product candidates that we successfully develop in situations in which we believe it is possible to access the market through a focused, specialized sales force. In particular, we believe that such a sales force could address commercial markets, such as the market for typhoid vaccines and other vaccines for travelers to developing countries, that overlap with markets for our biodefense products. We expect that we will selectively pursue collaboration arrangements in situations in which the collaborator has particular expertise or resources for the development or commercialization of our products or product candidates or to access particular markets.